Changing needs of community-acquired pneumonia

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue SUPPL.3, 2011, Pages

  Ramirez, Julio Alberto ^a   Anzueto, Antonio R ^b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Antimicrobial therapy; Clinical outcomes; PSI CURB 65 score

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; CLINDAMYCIN; ERYTHROMYCIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; DRUG EFFICACY; DRUG TREATMENT FAILURE; HAEMOPHILUS INFLUENZAE; HOSPITALIZATION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORAXELLA CATARRHALIS; RISK ASSESSMENT; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTERIA; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; HOSPITALIZATION; HUMANS; PNEUMONIA, BACTERIAL; PNEUMONIA, VIRAL; VIRUSES;

EID: 79955021835     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr094     Document Type: Article

References (64)

1. Heron M, Hoyert DL, Murphy SL et al. National Vital Statistics Reports. Deaths: Final Data for 2006. April 17, 2009. http://www.cdc.gov/nchs/data/nvsr/nvsr57/nvsr57_14.pdf (17 August 2010, date last accessed).
2. Niederman MS, McCombs JS, Unger AN et al. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820-37.
3. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2: S27-72.
4. DeFrances CJ, Hall MJ. 2005 National Hospital Discharge Survey. Adv Data 2007; (385): 1-19.
5. Agency for Healthcare Research and Quality. Pneumonia is the Most Common Reason for Hospitalization. http://www.ahrq.gov/research/sep08/0908RA40.htm (17 August 2010, date last accessed).
6. Curns AT, Holman RC, Sejvar JJ et al. Infectious disease hospitalizations among older adults in the United States from 1990 through 2002. Arch Intern Med 2005; 165: 2514-20.
7. Fry AM, Shay DK, Holman RC et al. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA 2005; 294: 2712-9.
8. Gilbert K, Fine MJ. Assessing prognosis and predicting patient outcomes in community-acquired pneumonia. Semin Respir Infect 1994; 9: 140-52.
9. Metlay JP. Antibacterial drug resistance: implications for the treatment of patients with community-acquired pneumonia. Infect Dis Clin North Am 2004; 18: 777-90.
10. España PP, Capelastegui A, Quintana JM et al. A prediction rule to identify allocation of inpatient care in community-acquired pneumonia. Eur Respir J 2003; 21: 695-701.
11. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-50.
12. Marrie TJ, Lau CY, Wheeler SL et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA 2000; 283: 749-55.
13. Ewig S, Schäfer H, Torres A. Severity assessment in community-acquired pneumonia. Eur Respir J 2000; 16: 1193-201.
14. Ewig S, Ruiz M, Mensa J et al. Severe community-acquired pneumonia: assessment of severity criteria. Am J Respir Crit Care Med 1998; 158: 1102-8.
15. British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Br J Hosp Med 1993; 49: 346-50.
16. Cordero E, Pachón J, Rivero A et al. Community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients: validation of severity criteria. Am J Respir Crit Care Med 2000; 162: 2063-8.
17. Lim WS, van der Eerden MM, Laing R et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377-82.
18. Marrie TJ, Wu L. Factors influencing in-hospital mortality in community-acquired pneumonia: a prospective study of patients not initially admitted to the ICU. Chest 2005; 127: 1260-70.
19. Bartlett JG. Is activity against 'atypical' pathogens necessary in the treatment protocols for community-acquired pneumonia? Issues with combination therapy. Clin Infect Dis 2008; 47 Suppl 3: S232-6.
20. Tenover FC, Goering RV. Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology. J Antimicrob Chemother 2009; 64: 441-6.
21. Labandeira-Rey M, Couzon F, Boisset S et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 2007; 315: 1130-3.
22. Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillinresistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005; 128: 2732-8.
23. xTAG RVP (Respiratory Viral Panel) Prescribing Information. Toronto, Ontario, Canada: Luminex Molecular Diagnostics, Inc., 2008.
24. CDC. Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) - United States, May-August 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 1071-4.
25. Ramirez JA, Srinath L, Ahkee S et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155: 1273-6.
26. Ramirez JA, Ahkee S. Early switch from IV antimicrobials to oral clarithromycin in patients with CAP. Infect Med 1997; 14: 319-23.
27. Ramirez JA. Switch therapy in adult patients with pneumonia. Clin Pulm Med 1995; 2: 327-33.
28. Ramirez JA, Vargas S, Ritter GWet al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999; 159: 2449-54.
29. Aliberti S, Amir A, Peyrani P et al. Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia. Chest 2008; 134: 955-62.
30. Ramirez J, Aliberti S, Mirsaeidi M et al. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis 2008; 47: 182-7.
31. Kothe H, Bauer T, Marre R et al. Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J 2008; 32: 139-46.
32. Janssens JP, Krause KH. Pneumonia in the very old. Lancet Infect Dis 2004; 4: 112-24.
33. Kaplan V, Clermont G, Griffin MF et al. Pneumonia: still the old man's friend? Arch Intern Med 2003; 163: 317-23.
34. Jackson ML, Neuzil KM, Thompson WW et al. The burden of community-acquired pneumonia in seniors: results of a populationbased study. Clin Infect Dis 2004; 39: 1642-50.
35. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med 2009; 360: 1418-28.
36. Mortensen EM, Kapoor WN, Chang CC et al. Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia. Clin Infect Dis 2003; 37: 1617-24.
37. Waterer GW, Kessler LA, Wunderink RG. Medium-term survival after hospitalization with community-acquired pneumonia. Am J Respir Crit Care Med 2004; 169: 910-4.
38. Johnstone J, Eurich DT, Majumdar SR et al. Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: a population-based cohort study. Medicine (Baltimore) 2008; 87: 329-34.
39. Bordon J, Wiemken T, Peyrani P et al. Decrease in long-term survival for hospitalized patients with community-acquired pneumonia. Chest 2010; 138: 279-83.
40. Gertz RE Jr, Li Z, Pimenta FC et al. Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. J Infect Dis 2010; 201: 770-5.
41. Jacobs MR. Antimicrobial-resistant Streptococcus pneumoniae: trends and management. Expert Rev Anti Infect Ther 2008; 6: 619-35.
42. Lynch JP III, Zhanel GG. Streptococcus pneumoniae: does antimicrobial resistance matter? Semin Respir Crit Care Med 2009; 30: 210-38.
43. Yu VL, Chiou CC, Feldman C et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered and clinical outcome. Clin Infect Dis 2003; 37: 230-7.
44. Lonks JR, Garau J, Gomez L et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35: 556-64.
45. Oster G, Berger A, Edelsberg J et al. 'Real-world' failure of initial antibiotic therapy in non-ICU community-acquired pneumonia (CAP) in US hospitals, 2000-2009. In: Abstracts of the Fiftieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 2010. Poster #L1-1044. American Society for Microbiology, Washington, DC, USA.
46. Vanderkooi OG, Low DE, Green K et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40: 1288-97.
47. Ruhe JJ, Hasbun R. Streptococcus pneumoniae bacteremia: duration of previous antibiotic use and association with penicillin resistance. Clin Infect Dis 2003; 36: 1132-8.
48. Hageman JC, Uyeki TM, Francis JS et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006; 12: 894-9.
49. Hidron AI, Low CE, Honig EG et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia. Lancet Infect Dis 2009; 9: 384-92.
50. Lam AP, Wunderink RG. The role of MRSA in healthcare-associated pneumonia. Semin Respir Crit Care Med 2009; 30: 52-60.
51. Dufour P, Gillet Y, Bes M et al. Community-acquired methicillinresistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 2002; 35: 819-24.
52. Mongkolrattanothai K, Boyle S, Kahana MD et al. Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis 2003; 37: 1050-8.
53. Vandenesch F, Naimi T, Enright MC et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003; 9: 978-84.
54. Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis 2005; 40: 562-73.
55. Fridkin SK, Hageman JC, Morrison M et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 352: 1436-44.
56. FDA. Guidance for Industry. Community-Acquired Bacterial Pneumonia: Developing Drugs for Treatment. March 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati on/Guidances/ucm123686. pdf (26 July 2010, date last accessed).
57. TeflaroTM [Ceftaroline Fosamil Prescribing Information (Draft)]. New York, NY: Forest Laboratories, Inc., 27 October 2010.
58. Laudano JB. Ceftaroline fosamil: a new broad-spectrum cephalosporin. J Antimicrob Chemother 2011; 66 Suppl 3: iii11-8.
59. File TM Jr, Low DE, Eckburg PB et al. on behalf of the FOCUS 1 investigators. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011; 66 Suppl 3: iii19-32.
60. Low DE, File TM Jr, Eckburg PB et al. on behalf of the FOCUS 2 investigators. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011; 66 Suppl 3: iii33-44.
61. Critchley IA, Eckburg PB, Jandourek A et al. Review of ceftaroline fosamil microbiology: integrated FOCUS studies. J Antimicrob Chemother 2011; 66 Suppl 3: iii45-51.
62. Rank DR, Friedland HD, Laudano JB. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 2011; 66 Suppl 3: iii53-9.
63. Drusano GL. What are the properties that make an antibiotic acceptable for therapy of community-acquired pneumonia? J Antimicrob Chemother 2011; 66 Suppl 3: iii61-7.
64. Jones RN, Farrell DJ, Mendes RE et al. Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study. J Antimicrob Chemother 2011; 66 Suppl 3: iii69-80.